Opinion

Emerging Biomarkers for Pancreatic Cancer: Potential For Early Diagnosis

Aaron Fishman*

Department of Radiation Medicine, Oregon Health & Science University, USA

Introduction

Pancreatic cancer is a formidable adversary in the realm of oncology, notorious for its late detection and poor prognosis. Often diagnosed at an advanced stage, when curative treatment options are limited, the five-year survival rate remains alarmingly low. The quest for early detection methods is critical in improving patient outcomes. Emerging biomarkers offer a beacon of hope, providing the potential for earlier diagnosis and better prognostication. This article delves into the latest advances in biomarker research for pancreatic cancer, highlighting their potential to revolutionize early diagnosis and treatment strategies [1].

Early detection is paramount in pancreatic cancer, as it significantly increases the chances of successful treatment. Traditional diagnostic methods, such as imaging and tissue biopsies, have limitations in detecting early-stage disease. Biomarkers—biological molecules found in blood, other body fluids, or tissues—hold promise for filling this gap. They can indicate the presence of cancer even before symptoms arise, enabling earlier intervention [2].

Among the most studied biomarkers for pancreatic cancer is carbohydrate antigen 19-9 (CA 19-9). While CA 19-9 is currently the most widely used biomarker in clinical practice, its specificity and sensitivity are suboptimal, particularly for early-stage disease. Elevated levels of CA 19-9 can also occur in other conditions, such as pancreatitis and liver disease, which complicates its use as a sole diagnostic tool. Therefore, the search for more reliable biomarkers continues [3].

Recent advancements in genomics and proteomics have identified several promising biomarkers for pancreatic cancer. Circulating tumor DNA (ctDNA) is one such marker that has garnered significant attention. ctDNA consists of fragments of DNA shed by tumors into the bloodstream. Detection of specific mutations, such as KRAS, in ctDNA can indicate the presence of pancreatic cancer at an early stage, providing a non-invasive method for early detection [4].

MicroRNAs (miRNAs) are another class of biomarkers showing potential in pancreatic cancer diagnosis. These small, non-coding RNA molecules regulate gene expression and play a role in cancer development. Specific miRNA expression profiles have been associated with pancreatic cancer, and detecting these miRNAs in blood samples could facilitate early diagnosis. Research is ongoing to validate the clinical utility of miRNAs as reliable biomarkers [5].

Proteomic approaches have also revealed potential biomarkers for pancreatic cancer. Proteins such as osteopontin and mesothelin have been identified as candidates for early detection. These proteins are involved in tumor growth and metastasis, and their elevated levels in blood or tissue samples could indicate the presence of pancreatic cancer. Combining proteomic data with other biomarker information can enhance diagnostic accuracy [6].

The tumor microenvironment plays a crucial role in pancreatic cancer progression, and biomarkers derived from this environment offer additional diagnostic avenues. For instance, exosomes—small vesicles released by cells—contain proteins, lipids, and RNA that reflect the tumor's molecular characteristics. Analyzing exosomal content from blood samples can provide insights into tumor biology and aid in early detection [7].

Glycan-based biomarkers are emerging as another promising area in pancreatic cancer research. Glycans are complex sugar molecules attached to proteins and lipids, and alterations in glycan structures are associated with cancer. Glycan profiling can differentiate between normal and cancerous cells, offering a potential tool for early diagnosis. Research is ongoing to identify specific glycan signatures that can serve as reliable biomarkers for pancreatic cancer [8].

Received 28-May-2024 Manuscript No IPP-24-20528 **Editor Assigned** 29-May-2024 Pre QC No IPP-24-20528 (PQ) **Reviewed** 12-Jun-2024 QC IPP-24-20528 **Revised** 17-Jun-2024 Manuscript No IPP-24-20528(R) **Published** 24-Jun-2024 DOI 10.35841/1590-8577-25.3.870

Correspondence Aaron Fishman,
Department of Radiation Medicine,
Oregon Health & Science University,
USA
E-mail fishmanaaron@ohsu.edu

Citation: Fishman A. Emerging Biomarkers for Pancreatic Cancer: Potential For Early Diagnosis. JOP. J Pancreas. (2024) 25:870

Integrating multiple biomarkers into a comprehensive panel is a strategy that holds great promise for improving diagnostic accuracy. A multi-marker approach can compensate for the limitations of individual biomarkers, providing a more robust and reliable diagnostic tool. Combining biomarkers such as ctDNA, miRNAs, proteins, and exosomes into a single test could enhance early detection rates and reduce false positives and negatives [9].

Advances in technology are facilitating the development and validation of new biomarkers. High-throughput sequencing, mass spectrometry, and bioinformatics tools enable the comprehensive analysis of genomic, transcriptomic, and proteomic data. These technologies allow researchers to identify and validate novel biomarkers with greater precision and speed, accelerating the translation of these discoveries into clinical practice [10].

Conclusion

Emerging biomarkers represent a significant advancement in the quest for early diagnosis of pancreatic cancer. From ctDNA and miRNAs to proteomic and glycan-based markers, these novel biomarkers offer the potential to detect pancreatic cancer at an earlier, more treatable stage. While challenges remain, the ongoing research and technological advancements provide hope for a future where early detection and improved patient outcomes are within reach. By integrating these biomarkers into clinical practice, we can move closer to transforming the landscape of pancreatic cancer diagnosis and treatment.

References

1. Wu J, Cai J. Dilemma and challenge of immunotherapy for pancreatic cancer. Digestive diseases and sciences. 2021 Feb;66(2):359-68.[PMID: 32140943]

2. Dose AM, Rhudy LM. Perspectives of newly diagnosed advanced cancer patients receiving dignity therapy during cancer treatment. Supportive Care in Cancer. 2018 Jan;26:187-95. [PMID: 28733697]

3. Barcellini A, Peloso A, Pugliese L, Vitolo V, Cobianchi L. Locally advanced pancreatic ductal adenocarcinoma: challenges and progress. OncoTargets and therapy. 2020 Dec 10:12705-20. [PMID: 33335406]

4. Wu AA, Jaffee E, Lee V. Current status of immunotherapies for treating pancreatic cancer. Current oncology reports. 2019 Jul;21:1-1. [PMID: 31101991]

5. Yu Z, Yang Y, Fang W, Hu P, Liu Y, Shi J. Dual tumor exosome biomarker co-recognitions based nanoliquid biopsy for the accurate early diagnosis of pancreatic cancer. ACS nano. 2023 Jun 8;17(12):11384-95. [PMID: 37288703]

6. Jafari S, Ravan M, Karimi-Sani I, Aria H, Hasan-Abad AM, Banasaz B, et al. Screening and identification of potential biomarkers for pancreatic cancer: An integrated bioinformatics analysis. Pathology-Research and Practice. 2023 Aug 2:154726. [PMID: 37591067]

7. Genco E, Modena F, Sarcina L, Björkström K, Brunetti C, Caironi M, et al. A Single-Molecule Bioelectronic Portable Array for Early Diagnosis of Pancreatic Cancer Precursors. Advanced Materials. 2023 Oct;35(42):2304102.[PMID: 37452695]

8. Hossen MB, Islam MA, Reza MS, Kibria MK, Horaira MA, Tuly KF, et al. Robust identification of common genomic biomarkers from multiple gene expression profiles for the prognosis, diagnosis, and therapies of pancreatic cancer. Computers in Biology and Medicine. 2023 Jan 1;152:106411.[PMID: 36502691]

9. Bamankar S, Londhe VY. The rise of extracellular vesicles as new age biomarkers in cancer diagnosis: promises and pitfalls. Technology in Cancer Research & Treatment. 2023 Jan;22:15330338221149266.[PMID: 36604966]

10. Xu Y, Wang Y, Höti N, Clark DJ, Chen SY, Zhang H. The next "sweet" spot for pancreatic ductal adenocarcinoma: Glycoprotein for early detection. Mass spectrometry reviews. 2023 Mar;42(2):822-43.[PMID: 34766650]

Citation: Fishman A. Emerging Biomarkers for Pancreatic Cancer: Potential For Early Diagnosis. JOP. J Pancreas. (2024) 25:870